Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Janus Living Inc. Class A-1 Common Stock vs Novavax Inc — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $29.3 (market cap $6.79B), while Novavax Inc trades at $12.4 (market cap $2.08B). The key difference: Janus Living Inc. Class A-1 Common Stock is far larger — about 3.3× Novavax Inc's market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.97% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| JAN | NVAX | |
|---|---|---|
Market Cap | $6.79B | $2.08B |
Volume | 1,802,875 | 8,501,139 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $12.82 |
52-Week Low | $22.88 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $6.88B | $1.66B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Novavax (NVAX) trades at $12.82, up 1.26% with a bullish technical outlook. The company reported strong revenue of $1.12B in 2025 and net income of $440.30M, marking a significant turnaround. Recent earnings beats and FDA approvals for updated COVID-19 vaccines support momentum. However, negative cash flow and high debt levels pose challenges.
The outlook is mixed: analyst consensus is 74% Buy with bullish technical signals, but profitability remains volatile. Key risks include cash burn and competitive pressure. Upside depends on successful Matrix-M platform adoption and partnership execution. Investors should weigh strong recent performance against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
